Abstract: A method of treating cancer in an immune-privileged site of a subject in need thereof is provided. The method comprises systemically administering to an area outside the immune-privileged site of the subject, a therapeutically effective amount of naive, viable cells of a tumor of the subject, the tumor being in the immune-privileged site so as to generate an immune response in the subject, thereby treating the cancer in the immune-privileged site of the subject.

Abstract: An external vein support comprising an elongate axial body including an axis, said body is plastically deformable by at least one of stretching, bending, twisting, and any combination thereof, relative to said axis.

Abstract: The invention provides a device (50) and system for treating a heart valve having an anchor (54, 56) and one or more sutures attached to the anchor. The anchor has an expanded deployed configuration and a low caliber undeployed configuration. A delivery in a heart includes catheter and a needle slidable in the lumen of the catheter. The distal end of the catheter is inserted through the myocardium of the heart until the catheter tip is juxtaposed to the underside of the valve leaflet to be treated. The leaflet is then pierced with tip of the needle. The needle is pushed until the anchor in its undeployed configuration passes through the needle tip and is released from the catheter. The anchor is then brought to its deployed configuration on one or both surfaces of the valve leaflet.

Abstract: Anti-CD24 antibodies and adjuvant combinations thereof with chemotherapeutic agents or toxins, which can be used to inhibit growth of CD24-expressing cancer cells and prevent and treat cancer are provided.

Abstract: The present invention relates to a polynucleotide construct encoding a fusion protein consisting of a domain which binds the immunoglobulin Fc region, genetically fused to a truncated form of Pseudomonas exotoxin A (PE). In particular, the invention discloses the fusion protein, ZZ-PE38, and further provides immunotoxins, formed from complexes of the fusion protein with antibodies for targeted cell killing.

Abstract: A measurement device is presented for use in an EEG measurement performed in the presence of a magnetic field. The device comprises a wiring array for connecting an electrodes arrangement to an electroencephalogram (EEG) monitoring device.

Abstract: Leptin muteins, in particular leptin antagonists, with increased binding affinity to leptin receptor are provided. These compounds as well as pharmaceutical composition comprising them are useful for the treatment of any disorder in which a non-desirable or deleterious activity of endogenous leptin or an altered innate immune response is implicated.

Abstract: Described is a removable shunt adapted for deployment along a brain-supplying artery into an aorta to supply blood to the artery during deployment of a stent-graft in the aorta, the removable shunt including a stiff segment that is stiff enough to remain at least partially open when between the aorta and the stent-graft and large enough to allow sufficient blood supply to the brain during the deployment of the stent-graft; and a mechanism for facilitating safe removal of the shunt from between the stent-graft and the aorta. Also described is a method of deploying a branch stent graft having a flaring portion in a blood vessel branching at a bifurcation from an aorta to connect to an aortic stent graft deployed in the aorta across the bifurcation, a branch stent-graft useful in the method, and a delivery system useful in the method.

Abstract: A novel laminin polypeptide comprising the amino acid sequence set forth by SEQ ID NO:3 is disclosed. Also disclosed are compositions-of-matter comprising a polysaccharide (e.g., hyaluronic acid) and the novel laminin polypeptide; or hyaluronic acid, a laminin polypeptide and an antioxidant (e.g., superoxide dismutase), as well as matrices and hydrogels comprising same which can be used for ex vivo or in vivo tissue formation and for treatment of pathologies characterized by diseased, damaged or loss of tissue.

Abstract: Described is a method for deploying a stent-graft in the aorta, the method including positioning a shunt to go along a portion of a brain-supplying artery (BSA) into the aorta; deploying a stent-graft in the aorta along a portion of the shunt; and removing the shunt. Also described is a removable shunt adapted for deployment along a brain-supplying artery into an aorta to supply blood to the artery during deployment of a stent-graft in the aorta, the removable shunt including a stiff segment that is stiff enough to remain at least partially open when between the aorta and the stent-graft and large enough to allow sufficient blood supply to the brain during the deployment of the stent-graft; and a mechanism for facilitating safe removal of the shunt from between the stent-graft and the aorta.

Abstract: A method of gait data collection, the method comprising collecting movement data, determining from the data a movement parameter that includes a third order derivative of position, comparing the movement parameter with a threshold value, and counting at least a near fall if the movement parameter exceeds the threshold value.

Abstract: A method of deploying a stent graft in a blood vessel with at least one side branch vessel, comprising: (a) forming a blood flow conduit between the branch vessel and the blood vessel such that a vessel section of the conduit is axially located inside the blood vessel and a branch section is positioned inside the branch vessel; (b) deploying the stent graft inside the blood vessel so that blood flow into said at least one side branch is blocked by the stent graft and continues through the blood flow conduit; (c) forming an opening suitable for allowing blood flow between the blood vessel and the branch vessel; and (d) interrupting blood flow in the vessel section of the conduit.

Abstract: An external vein support comprising an elongate axial body including an axis, said body is plastically deformable by at least one of stretching, bending, twisting, and any combination thereof, relative to said axis.

Abstract: A method of treating a CD24-related medical condition is disclosed. The method comprises administering to a subject in need thereof at least one siRNA molecule selected from the group consisting of SEQ ID NO: 1 to 4. Pharmaceutical compositions comprising same are also disclosed.

Abstract: The present invention relates to pharmaceutical composition comprising animal venom and using same in a method for the treatment of Systemic Inflammatory Response Syndrome (SIRS) and related pathologies.

Abstract: Anti-CD24 antibodies and adjuvant combinations thereof with chemotherapeutic agents or toxins, which can be used to inhibit growth of CD24-expressing cancer cells and prevent and treat cancer are provided.

Abstract: A novel laminin polypeptide comprising the amino acid sequence set forth by SEQ ID NO:3 is disclosed. Also disclosed are compositions-of-matter comprising a polysaccharide (e.g., hyaluronic acid) and the novel laminin polypeptide; or hyaluronic acid, a laminin polypeptide and an antioxidant (e.g., superoxide dismutase), as well as matrices and hydrogels comprising same which can be used for ex vivo or in vivo tissue formation and for treatment of pathologies characterized by diseased, damaged or loss of tissue.

Abstract: A method of diagnosing cancer or a pre-malignant lesion is disclosed. The method comprises determining a level of CD24 expressed on peripheral blood cells of a subject in need thereof, wherein the level of CD24 above a predetermined threshold is indicative of the cancer or the pre-malignant lesion.

Abstract: A method of treating cancer in an immune-privileged site of a subject in need thereof is provided. The method comprises systemically administering to an area outside the immune-privileged site of the subject, a therapeutically effective amount of naive, viable cells of a tumor of the subject, the tumor being in the immune-privileged site so as to generate an immune response in the subject, thereby treating the cancer in the immune-privileged site of the subject.

Abstract: A method of treating a CD24-related medical condition is disclosed. The method comprises administering to a subject in need thereof at least one siRNA molecule selected from the group consisting of SEQ ID NO: 1 to 4. Pharmaceutical compositions comprising same are also disclosed.